EcoR1 Capital, a venture capital firm, led a $115m Series B financing round in Neurogene, a genetic medicines provider. Existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed healthcare investment fund also participated. New investors include funds and accounts managed by BlackRock, funds managed by Janus Henderson Investors, Casdin Capital, Avidity Partners, Ascendant BioCapital, Arrowmark Partners, and Alexandria Venture Investments. “Gene therapy has generated tremendous hope for the many families and patients with severe genetic disorders. We believe our focus on improved product design, innovative technology, cutting-edge vector manufacturing and premier analytics will help fulfill the potential of genetic treatments. Proceeds from this round of financing will help us execute on our mission to develop safe and effective genetic therapies for patients and families living with neurological diseases,” Rachel McMinn, Ph.D., Neurogene Founder and Chief Executive Officer.